Due to the recent operating environment, Moderna has decided to abandon plans to build an mRNA drug active ingredient factory in Japan.

Moderna announced that, after careful consideration of the recent operating environment, it has decided not to continue with the construction plan for the mRNA drug substance factory led by its Japanese subsidiary, Moderna Japan. The facility for mRNA drug research and manufacturing led by Moderna Enzymatics has already been completed. Moderna stated that expanding its operations in Japan remains an important component of its strategic plan. If the commercial environment becomes favorable in the future, the company plans to reconsider the construction of the mRNA drug substance factory.